Last updated on October 2018

Novel INXN-4001 Triple Effector Plasmid in Heart Failure

Brief description of study

To evaluate the safety of retrograde coronary sinus infusion of a novel triple-effector plasmid (INXN-4001) in outpatient LVAD recipients as assessed by incidence of all study intervention - related adverse events occurring up to 6 months post-treatment

Clinical Study Identifier: NCT03409627

Contact Investigators or Research Sites near you

Start Over

Catherine MacDonald, BScN, MBA

University of Arizona Sarver Heart Center
Tucson, AZ United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.